Harold Davidson & Associates Inc. Purchases 2,538 Shares of Stryker Corporation $SYK

Harold Davidson & Associates Inc. grew its position in shares of Stryker Corporation (NYSE:SYK) by 41.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,687 shares of the medical technology company’s stock after buying an additional 2,538 shares during the period. Stryker accounts for 1.5% of Harold Davidson & Associates Inc.’s investment portfolio, making the stock its 17th largest position. Harold Davidson & Associates Inc.’s holdings in Stryker were worth $3,211,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Terra Alpha Investments LLC bought a new stake in Stryker during the third quarter worth about $1,216,000. Diversified Trust Co raised its holdings in shares of Stryker by 45.6% during the 3rd quarter. Diversified Trust Co now owns 12,445 shares of the medical technology company’s stock valued at $4,601,000 after buying an additional 3,899 shares in the last quarter. SVB Wealth LLC bought a new stake in Stryker in the 2nd quarter worth approximately $4,785,000. AXQ Capital LP purchased a new stake in Stryker in the second quarter worth approximately $567,000. Finally, National Pension Service boosted its stake in Stryker by 2.4% in the third quarter. National Pension Service now owns 683,867 shares of the medical technology company’s stock worth $252,805,000 after buying an additional 16,254 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $377.08 on Thursday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The firm has a market cap of $144.30 billion, a P/E ratio of 44.89, a P/E/G ratio of 2.16 and a beta of 0.87. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $404.87. The firm has a 50-day moving average of $359.13 and a 200-day moving average of $368.93.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same quarter in the prior year, the company posted $4.01 EPS. Stryker’s quarterly revenue was up 11.4% compared to the same quarter last year. Sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is presently 41.90%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on SYK shares. Truist Financial lowered their price objective on shares of Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Barclays reissued an “overweight” rating and issued a $469.00 price target on shares of Stryker in a research note on Monday, February 2nd. Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective on the stock in a research note on Tuesday, January 6th. BTIG Research boosted their target price on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Finally, Robert W. Baird set a $437.00 target price on Stryker in a report on Friday, January 30th. Twelve research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $426.94.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.